Time filter

Source Type

— The Global Loratadine market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Loratadine in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Loratadine Players in each region, with sales, price, revenue and market share for top 5 manufacturer, covering Merck Bayer Group Perrigo Sun Pharma Apotex Pfizer Sandoz Mylan SL PHARM Cadila Pharmaceutical Avail 10% Discount on Single User License. Valid for the period from 15th May 2017 to 15th June 2017 Get a Free PDF Sample of Market Report at: http://www.orbisresearch.com/contacts/request-sample/299295 Market Segment by Regions, this report splits Global into several key Regions, with sales, revenue, market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada and Mexico) Asia-Pacific (China, Japan, Southeast Asia, India and Korea) Europe (Germany, UK, France, Italy and Russia etc. South America (Brazil, Chile, Peru and Argentina) Middle East and Africa (Egypt, South Africa, Saudi Arabia) Split by Product Types, with sales, revenue, price, market share of each type, can be divided into Loratadine Tablet Loratadine capsules Loratadine syrup Split by applications, this report focuses on sales, market share and growth rate of Loratadine in each application, can be divided into Adult Drug Pediatric Drug Avail 15% Discount on Corporate Users License Valid for the period from 15th May 2017 to 15th June 2017 Buy the Report@ http://www.orbisresearch.com/contact/purchase/299295 About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/2017-top-5-loratadine-manufacturers-in-north-america-europe-asia-pacific-south-america-middle-east-and-africa


Lashkari P.D.,MTS India | Mody V.,Cadila Pharmaceutical Ltd.
International Journal of ChemTech Research | Year: 2010

Plants have been used for the treatment of diseases all over the world before the advent of modern clinical drugs and are known to contain substances that can be used for therapeutic purposes or as precursors for the synthesis of useful drugs. Thus over 50% of these modern drugs are of natural products origin and as such these natural products play an important role in drug development in the pharmaceutical industry. The sensitivity towards the microorganism was increased as concentration is increases. Arowash liquid has (30 - 80 μl) maximum sensitivity towards Staphylococcus aureus while it has low sensitivity towards the Bacillus subtilis. Arowash liquid has similar effect with the standard drug (Nitrofurazone).


Mehta J.,Cadila Pharmaceutical Ltd. | Patidar K.,Cadila Pharmaceutical Ltd. | Vyas N.,Cadila Pharmaceutical Ltd.
E-Journal of Chemistry | Year: 2010

A simple and precise reversed phase high performance liquid chromatographic method has been developed and validated for the quantification of benzalkonium chloride (BKC) preservative in pharmaceutical formulation of latanoprost eye drops. The analyte was chromatographed on a Waters Spherisorb CN, (4.6x250 mm) column packed with particles of 5 μm. The mobile phase, optimized through an experimental design, was a 40:60 (v/v) mixture of potassium dihydrogen orthophosphate buffer (pH 5.5) and acetonitrile, pumped at a flow rate of 1.0 mL/min at maintaining column temperature at 30 oC. Maximum UV detection was achieved at 210 nm. The method was validated in terms of linearity, repeatability, intermediate precision and method accuracy. The method was shown to be robust, resisting to small deliberate changes in pH, flow rate and composition (organic ratio) of the mobile phase. The method was successfully applied for the determination of BKC in a pharmaceutical formulation of latanoprost ophthalmic solution without any interference from common excipients and drug substance. All the validation parameters were within the acceptance range, concordant to ICH guidelines.


A simple, precise, shorter runtime and stability indicating reversephase high performance liquid chromatographic method has been developed and validated for the quantification of benzalkonium chloride (BKC) preservative in pharmaceutical formulation of sparfloxacin eye drop. The method was successfully applied for determination of benzalkonium chloride in various ophthalmic formulations like latanoprost, timolol, dexametasone, gatifloxacin, norfloxacin, combination of moxifloxacin and dexamethasone, combination of nepthazoline HCl, zinc sulphate and chlorpheniramine maleate, combination of tobaramycin and dexamethasone, combination of phenylephrine HCl, naphazoline HCl, menthol and camphor. The RP-LC separation was achieved on an Purospher Star RP-18e 75 mm × 4.0 mm, 3.0 μ in the isocratic mode using buffer: acetonitrile (35: 65, v/v), as the mobile phase at a flow rate of 1.8 mL/min. The methods were performed at 215 nm; in LC method, quantification was achieved with PDA detection over the concentration range of 50 to 150 μg/mL. The method is effective to separate four homologs with good resolution in presence of excipients, sparfloxacin and degradable compound due to sparfloxacin and BKC within five minutes. The method was validated and the results were compared statistically. They were found to be simple, accurate, precise and specific. The proposed method was validated in terms of specificity, precision, recovery, solution stability, linearity and range. All the validation parameters were within the acceptance range and concordant to ICH guidelines.


Mehta J.,Cadila Pharmaceutical LTD. | Patidar K.,Cadila Pharmaceutical LTD. | Patel V.,Cadila Pharmaceutical LTD. | Kshatri N.,Cadila Pharmaceutical LTD. | Vyas N.,Cadila Pharmaceutical LTD.
Analytical Methods | Year: 2010

The intended purpose of this work is to develop and validate a dissolution test for misoprostol tablets containing 200 μg misoprostol [1% in hydroxypropyl methylcellulose {HPMC}] using a reverse-phase liquid chromatographic method. After testing sink conditions, dissolution medium and stability of the drug, the best conditions were: paddle at 50 rotations per minute (rpm) stirring speed, deaerated water dissolution medium with volume of 500 ml, as per very low label content of the drug substance & drug product. The method was validated to meet requirements for a global regulatory filing and this validation included specificity, precision, linearity and accuracy. Release of more than 85% of the label amount was achieved over 30 min in the medium through out the study. The dissolution test developed was adequate for its purpose and could be applied for quality control of misoprostol formulation dosage form. © The Royal Society of Chemistry 2010.


Trivedi H.K.,Cadila Pharmaceutical Ltd | Patel M.C.,P.A. College
International Journal of ChemTech Research | Year: 2010

A simple, short, rapid, sensitive and robust reversed phase-HPLC method was developed and validated to measure the amount of Azithromycin in dissolution profile. An isocratic elution of filtered sample was performed on cosmosil RP18 (50mm x 4.6mm), 5μm column with phosphate buffer (pH 7.5) & methanol (35:65 v/v) as mobile phase and UV detection at 210 nm. Mobile phase was delivered at flow of 2.0mL/min and maintaining the column temperature at 50°C and quantification was achieved with reference to the external standards. The total run time is about three minutes only. The Azithromycin and two degradable impurities are separated with good resolution within three minutes. The linearity for concentrations between 70μg/mL and 840μg/mL (12.5% to 150.0%) for Azithromycin was established. The percentage RSD during intra and inter-day precision was about 2.4 & 3.7% which is less than 6.0%. The method was successfully applied for the determination of Azithromycin in a pharmaceutical formulation without any interference from common excipients, diluent and dissolution medium. In addition, standard and sample solutions stability and robustness were demonstrated. A statistical design of experiments was used for the robustness evaluation of HPLC method. All results were accepted and confirmed that the method is suitable for its intended applications. All the validation parameters were within the acceptance range, and concordant to ICH guidelines.


Trivedi H.K.,Cadila Pharmaceutical Ltd | Patel M.C.,P.A. College
International Journal of ChemTech Research | Year: 2010

A simple reversed-phase high performance liquid chromatography has been developed and employed for the analysis of Omeprazole and its related substances in bulk material and commercial dosage forms. A gradient elution of filtered sample was performed on Zorbax XDB C8 (150 x 4.6), 5μ column with Glacine buffer (pH -8.8) as a mobile phase-A, Acetonitrile: Methanol (83:17) as a mobile phase-B and UV detection at 302 nm. Mobile phase was delivered at flow of 1.2 mL/min and at maintaining the column temperature at 25oC, quantification was achieved with reference to the external standards. The active ingredient-omeprazole was successfully separated from its all related substances, including process impurities and other possible impurities of oxidation and decomposition. The excipients did not interfere with the determination of omeprazole and its related compound in commercial dosage formulations. The method was rapid, simple, accurate and reproducible. It was not only successfully employed for the assay of omeprazole in bulk material and pharmaceutical dosage forms but also for the determination of its related substances. A statistical design of experiments was used for the robustness evaluation of HPLC analysis method. All results were acceptable and confirmed that the method is suitable for its intended use.


Mehta J.,Cadila Pharmaceutical LTD. | Patel V.,Cadila Pharmaceutical LTD. | Kshatri N.,Cadila Pharmaceutical LTD. | Vyas N.,Cadila Pharmaceutical LTD.
Analytical Methods | Year: 2010

A challenging and multipurpose stability-indicating HPLC method is developed and validated for the quantification of latanoprost, timolol, benzalkonium chloride (BKC) and related substances in the presence of their degradation products in ophthalmic solution. Various stress conditions, e.g. acid, base, oxidation, heat, UV radiation and heat were employed to assess the stability-indicating nature of the method. A strategic experimental approach was implemented for the method development. The desired chromatographic separation was achieved on a reverse phase cyano column {Hypersil BDS CN (250 × 4.6 mm), 5 μm} under gradient elution conditions. A mixture of phosphate buffer of pH 3.2, acetonitrile and methanol was used as the mobile phase. The determination was carried out at 295 nm and 210 nm. Due to the very low content of latanoprost (0.005%) in the formulation, the injection volume was optimized as 80 μl in order to achieve an optimum response. In totality, peaks of latanoprost and its two known impurities, four BKC homologs, timolol and its known impurities were obtained with a minimum resolution of 3.0. This sensitive method was found to be precise and linear through out the range with a lowest quantification of 0.068 μg ml -1 for 15-keto latanoprost, 0.030 μg ml -1 for latanoprost acid, 0.018 μg ml -1 for latanoprost (unknown impurity), 0.011 μg ml -1 for timolol impurity I and 0.013 μg ml -1 for timolol (unknown impurity). The method was validated according to ICH guidelines. This versatile method can be used as a combined assay and related substance method for said ophthalmic solution formulation. © 2010 The Royal Society of Chemistry.


PubMed | Cadila Pharmaceutical Ltd.
Type: Journal Article | Journal: Scientia pharmaceutica | Year: 2012

A stability-indicating reversed phase ultra performance liquid chromatographic (RP-UPLC) method was developed for the determination of related substances in rosuvastatin calcium (ROSV) tablet dosage form. The chromatographic separation was achieved on an Acquity BEH C18 (100 mm 2.1 mm, 1.7 m) column with mobile phase containing a gradient mixture of solvent-A (0.1% trifluoroacetic acid) and solvent-B (methanol). The eluted compounds were monitored at 240 nm and the run time was 10.0 min. Degradation behavior of the ROSV was studied under various degradation stress conditions. Four major unknown degradation products (late eluting impurities) were found in acid stress condition and two unknown degradation products were found in oxidative stress condition. The developed method separates (six) unknown impurities, (three) known impurities and ROSV substance from each other, providing the stability-indicating power of the method. The developed RP-UPLC method was validated according to the International Conference on Harmonization (ICH) guidelines. The developed and validated RP-UPLC method is LC-MS compatible and can be applied for identification of eluted unknown impurities of ROSV.

Loading Cadila Pharmaceutical Ltd collaborators
Loading Cadila Pharmaceutical Ltd collaborators